New ulcerative colitis drug shows promise in early trial
NCT ID NCT07029971
First seen Oct 31, 2025 · Last updated Jun 05, 2026 · Updated 29 times
Summary
This early-phase study tested a single injection of BB-TL1A-VIAL-HLE in 16 people—first in healthy volunteers and then in patients with moderate-to-severe ulcerative colitis. The main goal was to check safety and tolerability, and to see if the drug could improve colon inflammation after 12 weeks. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Arcadia Pittwater Private Hospital (Operated by Battery Bio)
Warriewood, New South Wales, 2102, Australia
-
Dymocks Building, WellShare Site
Sydney, New South Wales, 2000, Australia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.